Literature DB >> 2745330

Mechanisms of hypotension produced by platelet-activating factor.

F R Laurindo1, R E Goldstein, N J Davenport, D Ezra, G Z Feuerstein.   

Abstract

Platelet-activating factor (PAF) is a phospholipid mediator that induces cardiovascular collapse and release of the secondary mediator thromboxane A2 (TxA2). To clarify mechanisms involved in this collapse and, specifically, the relative contribution of left ventricular and right ventricular dysfunction, we studied 12 open-chest pigs. PAF infusion (0.04-0.28 nmol.kg-1.min-1) induced a 5- to 120-fold increase in pulmonary vascular resistance, a 75-98% fall in cardiac output, and systemic arterial hypotension. Right ventricular failure was indicated by chamber enlargement, decreased shortening, and increased right atrial pressures. In contrast, left ventricular dysfunction was accompanied by decreases in chamber dimensions and filling pressures that were unresponsive to volume expansion. U 46619 (a stable TxA2 analogue) and mechanical pulmonary artery constriction induced changes similar to PAF. In 11 additional closed-chest pigs, TxA2 blockade with indomethacin attenuated the PAF-induced rise in pulmonary vascular resistance, right ventricular dysfunction, and systemic hypotension. A specific TxA2 synthase inhibitor, OKY-046, also diminished hemodynamic effects of PAF in six other pigs. Tachyphylaxis was not observed in five pigs repeatedly given PAF. We conclude that acute right ventricular failure as the result of severe increase in pulmonary vascular resistance is the primary mechanism early in the course of PAF-induced shock in the pig. PAF-induced release of TxA2 may contribute significantly to these events.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2745330     DOI: 10.1152/jappl.1989.66.6.2681

Source DB:  PubMed          Journal:  J Appl Physiol (1985)        ISSN: 0161-7567


  11 in total

Review 1.  PAF. A review of its effects, antagonists and possible future clinical implications (Part II).

Authors:  M Koltai; D Hosford; P Guinot; A Esanu; P Braquet
Journal:  Drugs       Date:  1991-08       Impact factor: 9.546

Review 2.  Cardiovascular effects of platelet-activating factor.

Authors:  R E Goldstein; G Z Feuerstein; L M Bradley; J J Stambouly; F R Laurindo; N J Davenport
Journal:  Lipids       Date:  1991-12       Impact factor: 1.880

3.  Nitric oxide (NO) modulation of PAF-induced cardiopulmonary action: interaction between NO synthase and cyclo-oxygenase-2 pathways.

Authors:  F Fabi; R Calabrese; T Stati; P del Basso
Journal:  Br J Pharmacol       Date:  2001-10       Impact factor: 8.739

4.  Oxygen radicals inhibit human plasma acetylhydrolase, the enzyme that catabolizes platelet-activating factor.

Authors:  G Ambrosio; A Oriente; C Napoli; G Palumbo; P Chiariello; G Marone; M Condorelli; M Chiariello; M Triggiani
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

5.  Mechanisms of pulmonary vasoconstriction and bronchoconstriction produced by PAF in the guinea-pig: role of platelets and cyclo-oxygenase metabolites.

Authors:  L Argiolas; F Fabi; P del Basso
Journal:  Br J Pharmacol       Date:  1995-01       Impact factor: 8.739

6.  Ipratropium bromide protects against bronchoconstriction during bronchoscopy.

Authors:  H Inoue; H Aizawa; S Takata; H Koto; K Matsumoto; M Shigyo; N Hara
Journal:  Lung       Date:  1994       Impact factor: 2.584

7.  Inhibition of PAF-acether effects on isolated guinea pig hearts by zinc ions (Zn2+).

Authors:  A Evangelou; V Kalfakakou; J Benveniste; B Arnoux
Journal:  Biol Trace Elem Res       Date:  1995-10       Impact factor: 3.738

8.  Platelet-activating factor causes ventilation-perfusion mismatch in humans.

Authors:  R Rodriguez-Roisin; M A Félez; K F Chung; J A Barberà; P D Wagner; A Cobos; P J Barnes; J Roca
Journal:  J Clin Invest       Date:  1994-01       Impact factor: 14.808

9.  Effects of PAF on cardiac function and eicosanoid release in the isolated perfused rat heart: comparison between normotensive and spontaneously hypertensive rats.

Authors:  C Giessler; K Pönicke; C Steinborn; O E Brodde
Journal:  Basic Res Cardiol       Date:  1995 Jul-Aug       Impact factor: 17.165

10.  Involvement of nitric oxide and eicosanoids in platelet-activating factor-induced haemodynamic and haematological effects in dogs.

Authors:  K Noguchi; T Matsuzaki; N Shiroma; Y Ojiri; M Sakanashi
Journal:  Br J Pharmacol       Date:  1996-06       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.